BACKGROUND: Age-adjusted stroke incidence has decreased over the past 50 years, likely as a result of changes in the prevalence and impact of various stroke risk factors. An updated version of the Framingham Stroke Risk Profile (FSRP) might better predict current risks in the FHS (Framingham Heart Study) and other cohorts. We compared the accuracy of the standard (old) and of a revised (new) version of the FSRP in predicting the risk of all-stroke and ischemic stroke and validated this new FSRP in 2 external cohorts, the 3C (3 Cities) and REGARDS (Reasons for Geographic and Racial Differences in Stroke) studies.
T he Framingham Stroke Risk Profile (FSRP) was originally described in 1991. 1 It integrates the effect of age, sex, and baseline measurements of various vascular risk factors: systolic blood pressure (SBP), use of antihypertensive medications, presence or absence of left ventricular hypertrophy on electrocardiography (ECG-LVH), prevalent cardiovascular disease (CVD), current smoking status, and current or previous atrial fibrillation (AF) and diabetes mellitus (DM) to describe a 10-year probability of incident stroke. Thus, in a 70-year-old man with elevated levels of 1 risk factor, an SBP of 160 mm Hg, the risk could vary from 8% in the absence of 6 other risk factors to 85% in the presence of all 6. An aggregate FSRP score is assigned on the basis of the presence or absence (or levels) of individual stroke risk factors and a hazard ratio (HR) associated with each factor. These HRs were derived from data on baseline stroke risk factors gathered in the late 1960s and 1970s and prospective surveillance for incident stroke over the 1970s and 1980s. This old FSRP has been validated in other cohorts, 2 is recommended by the American Heart Association, and is used by clinicians to predict individual risk of patients. It has also been used by many studies as an aggregate measure of vascular burden inimical to the brain 3 and as a baseline risk predictor to assess the incremental utility of circulating, genetic, or imaging biomarkers thought to improve stroke risk prediction. [4] [5] [6] [7] [8] However, several studies including Framingham cohorts' data have demonstrated that age-adjusted incidence of stroke has declined over the past 50 years [9] [10] [11] and even in the 3 decades since data for the FSRP were first collated. 11 When the FSRP was applied to a French study carried out in the early 2000s, it clearly overestimated risk, and this has since been observed in the REGARDS study (Reasons for Geographic and Ethnic Differences in Stroke). 12, 13 This overestimation could have been the result of several factors, including population differences (It has been postulated that genetic and lifestyle differences could reduce stroke risk in France compared with the United States) and the fact that an outdated risk profile was being applied to a more contemporaneous sample. The latter appears likely because stroke rates and prevalence of several stroke risk factors have declined whereas stroke preventive treatments have improved in effectiveness in the past 25 years since the FSRP was first described. 9, [14] [15] [16] We examined this question by comparing the predictive accuracy of the old and an updated new FSRP in 3 settings: the more recent FHS (Framingham Heart Study) data, the REGARDS, and the 3C study (3 Cities) samples.
We present an updated new FSRP based on risk factor prevalence and HRs observed in the FHS over the past 2 decades (1990 on) and validate it in the 2 external samples.
METHODS Populations

In the FHS
Our study sample comprised the Framingham Original cohort enrolled in 1948 and examined biennially since then and the Framingham Offspring and Spouses of Offspring enrolled in 1971 and re-examined approximately once every 4 years since then. 17 The sample used in developing the old FSRP (n=5734, age ≥55 years) was created by pooling 2 nonoverlapping 10-year periods, with data contributed by individuals attending the 9th Original (1964 Original ( -1968 and 14th Original (1975 Original ( -1978 cohort examinations. The contemporary epoch (n=5072, age ≥55 years) was created by pooling 2 nonoverlapping 10-year periods, with data contributed by individuals attending the 21st Original (1988-92) What Are the Clinical Implications?
• The Framingham Stroke Risk Profile is the most widely used stroke risk prediction tool.
• It has been recommended by the American Heart Association and used in doctors' offices to educate patients and to plan treatments.
• In research settings, it helps assess the incremental predictive value of genetic, circulating, or imaging biomarkers.
• Furthermore, it is a good marker of cumulated vascular brain injury and predicts dementia risk.
• Incidence of stroke, stroke risk factors, and treatments for stroke have changed greatly in the past 25 years.
• The new version retains the simplicity of the original tool but updates it to improve accuracy.
and 84 years of age at the baseline examination. In FHS, all participants were followed up for 10 years or until 2010 and provided informed consent approved by the Institutional Review Board at the Boston University Medical Center.
In REGARDS
The sample was enrolled between 2003 and 2007 and comprised 30 239 participants ≥45 years of age, with 45% men, 55% women, 42% black, and 58% white. Participants were drawn from all 48 states in the lower continental United States with oversampling in the Stroke Buckle and Stroke Belt. Potential participants were identified from commercially available lists from Genesys, Inc (Daily City, CA) and were contacted through a personalized mailing followed by a computer-assisted phone interview during which verbal consent was obtained and information on demographics and stroke risk factors was recorded. A trained health professional visited the participants at their homes to obtain written informed consent, to perform ECGs, and to obtain measures of blood pressure, height, weight, and blood and urine sampling. Follow-up phone contact was subsequently made at 6-month intervals for surveillance of suspected stroke events, with medical records for suspected events retrieved and adjudicated by a panel of physicians. The study was approved by the Institutional Review boards at all participating universities, and written informed consent was obtained from all participants. 18 Data on up to 5 years of follow-up were included in this analysis.
In 3C
Enrollment took place between 1999 and 2001 among individuals selected from the electoral rolls of 3 French cities (Bordeaux, Dijon, and Montpellier) who were at least 65 years old and were not institutionalized at entry. Follow-up visits occurred biennially. The study protocol was approved by the ethics committee of the University Hospital of KremlinBicêtre. Written informed consent and permission to access medical records were obtained from each participant. Participant follow-up data for to up to 10 years were included in this analysis.
Definition of Stroke Risk Factors
In FHS Data on age, presence and absence of individual stroke risk factors, and levels of these risk factors were collated from each baseline examination. Age and SBP were treated as continuous variables, whereas other risk factors were treated as dichotomous variables. SBP was recorded as the mean of 2 physician-recorded measurements made on the left arm of the seated subject with a mercury column sphygmomanometer and a cuff of appropriate width. Baseline CVD was recorded as present if coronary artery disease, congestive heart failure, or peripheral vascular disease had been documented in the participant at or before the baseline examination. We defined baseline DM as a fasting plasma glucose level ≥7 mmol/L, a casual plasma glucose level ≥11.1 mmol/L, or the use of insulin or an oral hypoglycemic drug at or before the baseline examination. 19 Current cigarette smoking was defined as smoking in the year before the baseline examination. We omitted ECG-LVH because its prevalence is very low in the contemporary FHS sample (1.6%) and these data were not available in the 3C study. Participants were considered to have prevalent AF if this arrhythmia was noted by a Framingham cardiologist on any ECG done at or before the baseline examination. 20 
In REGARDS
Age, sex, use of antihypertensive medications, and smoking were recorded as self-reported in the initial phone interview. The definition of DM was identical to that used in FHS, and SBP was also directly recorded as the average of 2 seated measurements obtained by a health professional. Nonstroke events were based only on the history and review of study ECG; thus, heart disease was defined as self-report of myocardial infarction, coronary artery bypass surgery, angioplasty, or stenting or ECG evidence of myocardial infarction. Determination of AF was by self-report of a physician diagnosis or ECG evidence at baseline. ECG-LVH was determined as in FHS in two thirds of the participants. However, in a third of the participants (those initially enrolled), ECG-LVH was estimated with a 7-lead rather than the standard 12-lead ECG. 21 
In 3C
Covariates (age, sex, medication use, current smoking status) were defined in an identical manner as in FHS on the basis of an in-person interview except that 3 measures of SBP were obtained with a digital electronic tensiometer (OMRON M4) and DM was defined as being present if the participant was on hypoglycemic treatment (insulin or oral blood glucose-lowering drugs) or if the fasting plasma glucose level at the baseline examination was >1.26 g/dL (7 mmol/L); DM was not diagnosed on the basis of random blood sugars. As in REGARDS, a subject was classified as having CVD history when it was evident on baseline ECG or if the participant reported a history of myocardial infarction, coronary bypass, or angioplasty. In addition, in 3C, as in the FHS, CVD was considered present if there was a history of vascular surgery for lower-limb arteritis. AF was determined as in REGARDS, and ECG-LVH data were not extracted.
Definition of Stroke
In FHS
Details of stroke surveillance and the protocol for determining the diagnosis and type of stroke have been published previously. 1, 22 Stroke was defined as an acute-onset focal neurological deficit of vascular origin, persisting for >24 hours, concordant with the World Health Organization definition; both ischemic and hemorrhagic strokes were included. Individual stroke subtypes were categorized according to an algorithm based on pre-established diagnostic criteria that include clinical features, imaging studies and other laboratory criteria, noninvasive vascular studies, cardiac evaluations for a source of embolus and, when available, information from autopsy studies. 23 Subgroup analysis was confined to the largest subgroup, that is, ischemic strokes; these were diagnosed if a focal neurological deficit was documented and the imaging showed no hemorrhage, imaging showed an ischemic infarct that correlated with the clinical deficit, or an ischemic infarct was documented at autopsy. Cranial computed 
In 3C
At each follow-up examination, information was collected on suspicion of stroke occurrence. In participants who reported incident stroke (during interview or by self-administered questionnaire), further medical data were collected from general practitioners, specialists, and hospital records when possible. In case of fatal events, emergency medical services and hospital records were used, and if they were unavailable, family physicians and family members were interviewed. An incident stroke was defined as a new focal neurological deficit of sudden or rapid onset, of presumed vascular origin, that lasted ≥24 hours, or leading to death. An end-point adjudication committee reviewed source documentation and adjudicated diagnosis of stroke according to the criteria of the World Health Organization.
Statistical Analyses
For all the analyses, we considered 4 samples: the FHS sample used in these analyses (called new FHS sample), the FHS sample that the old FSRP had been derived from (called old FHS sample), the REGARDS sample, and the 3C sample. All analyses were run separately by sex. We first examined the crude 5-and 10-year probability of all stroke and ischemic stroke in each sample. We then examined the distributions of risk factors in each sample. Next, we investigated the associations between risk factors and incident stroke in each of the 4 samples. We related the old FSRP (with ECG-LVH set to 0) and the new FSRP to the outcome of first stroke using Cox models in the most recent 2 decades of data on the FHS cohorts (new FHS sample) and in the entire follow-up period for 3C and REGARDS. The old FSRP uses the previously published means of the risk factors, HRs, and estimates of incident stroke. The new FSRP updates the means of the risk factors to reflect current prevalence, updates the estimate of incident stroke to reflect current rates, and updates the HRs to reflect current associations. We used the same risk factors identified in the original FSRP except for LVH, both because estimation of presence or absence of LVH can vary substantially depending on the criteria used, making it less suitable for incorporation into a risk score, 21 and because we showed that in the new FHS sample, it does not improve the risk score performances in either sex.
To take into account differences in age at enrollment between the FHS, REGARDS, and 3C studies, we tested interactions of age (studied as 55-64 versus ≥65 years) with various risk factors, and when any interaction was significant, an interaction term was included in the model (only the interaction of age with DM was significant).
We compared the various models using a modification of the Hosmer-Lemeshow calibration χ 2 statistic for Cox models. 24, 25 This statistic measures how closely the outcomes predicted by a given model approximate the observed outcomes. The performance of the Hosmer-Lemeshow calibration statistic for the Cox model can be biased if there is substantial censoring; however, in the FHS data set, which has a censoring rate of <5%, this is not a concern. 26 We also compared the various models (the 2 versions of the old FSRP and the new FSRP) on each study using the c statistic, a measure analogous to the area under the curve of a receiveroperating characteristic curve. The c statistic 27 estimates discrimination, the ability of each model to correctly distinguish between individuals who do and those who do not develop an incident stroke over a 5-year period (REGARDS) and 10-year period (new FHS, 3C) of observation. All analyses were undertaken with SAS version 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
The mean age-adjusted 10-year stroke probability is 6.9% in the new FSRP sample compared with 9.6% in the old FSRP sample, 1 suggesting a decrease of 28% over 20 years, consistent with prior estimates. 9, 21 Tables 1 and 2 show the incidence of total stroke and ischemic stroke in each study sample and the number of individuals at baseline in each study. In the new FHS, over 10 years of follow-up, there were a total of 277 incident strokes (247 ischemic strokes), 144 (129 ischemic strokes) in women. In individuals ≥55 years of age, the probability of all stroke over 5 years of follow-up did not differ for men between the new FHS sample and REGARDS (2.9% versus 3.1%), whereas it was higher for women in REGARDS (2.2% versus 2.7%). Similar trends were seen for ischemic strokes.
In individuals ≥65 years old, the probability of stroke over 10 years of follow-up is still at least twice as high in the new FHS sample as in the 3C study, for men and women, and for all stroke and ischemic stroke. Table 3 shows the sex-specific prevalence at baseline of stroke risk factors in the different cohorts. In men, between the old and the new FHS samples, there has been a substantial decline in the prevalence of smoking (from 34% to 12%), whereas the prevalences of AF, DM, and antihypertensive medication use have increased, ranging from a 50% increase for DM to a 160% increase for antihypertensive treatments. In women, similar trends toward a decreased prevalence of smoking were observed, as were increases, but to a lesser extent than in men, for AF, DM, and antihypertensive medication use. The comparison between the new FHS sample and REGARDS among men ≥55 years of age showed a higher prevalence of CVD, DM, and antihypertensive medication use among REGARDS participants. Within REGARDS, prevalence of risk factors differed between white and black male participants; in the latter, a higher prevalence of smoking, DM, and hypertension was observed. The comparison between the new FHS and REGARDS samples among women ≥55 years of age also showed a higher prevalence of AF, DM, and antihypertensive medication use among RE-GARDS participants. Within REGARDS, the prevalence of risk factors differed between white and black female participants; in the latter, a higher prevalence of DM and hypertension was observed. Comparison between the new FHS and 3C samples among individuals ≥65 years of age suggests that for most risk factors, in men as in women, prevalence tended to be lower in the 3C study, except for DM in individuals ≥65 years of age, which had a similar prevalence across cohorts, and mean SBP, which was higher on average in 3C men than in FHS men. Table 4 shows the sex-specific, multivariable HRs of the various stroke risk factors on total stroke among men and women in the old and new FHS samples, REGARDS, and 3C studies.
Prevalence of the Stroke Risk Factors
Impact of the Stroke Risk Factors
Between the old and new FHS samples, in men, the impact of AF on stroke risk has decreased from an HR of 1.82 to 1.08. In the new FHS sample, among men, an interaction between age and DM was observed, the impact of DM on stroke risk being much higher in those <65 years of age (HR=3.87 versus 1.41). Comparing the old and new FHS samples shows that in women the impact of prevalent CVD on stroke risk has decreased from an HR of 1.55 to 0.97. In the new FHS, in women as in men, an interaction between age and DM was noted, the impact of DM on stroke risk being much higher in those <65 years of age (HR=2.92 versus 1.07). In a comparison of the new FHS and REGARDS studies, the associations were overall stronger in REGARDS than in the new FHS sample, for men and for women, especially for smoking and AF; exceptions were the risk factors of hypertension in men and AF and DM in women, which were more strongly associated with increased stroke risk in FHS than in REGARDS. Within the REGARDS sample, patterns of association were quite consistent between white and black participants.
Comparisons of risk factor impacts on stroke risk between the new FHS and 3C samples showed that for both men and women, age and SBP were independent predictors of total stroke risk in both cohorts. In 3C, for both men and women, AF was also an independent predictor of total stroke. In the new FHS sample, current smoking and prevalent DM in individuals 55 to 64 years of age were independent predictors of future stroke risk in both men and women, whereas prevalent CVD and antihypertensive treatment were independent predictors of future stroke risk in men only and AF was an independent predictor of future stroke risk in women only. Patterns of association of risk factors with the risk of ischemic stroke were similar to those observed with all stroke and are reported in Table I in the onlineonly Data Supplement.
Stroke Risk Prediction Based on Old FSRP and New FSRP Table 5 shows the sex-specific c statistic derived from the old FSRP (with ECG-LVH set to 0 for all individuals); a version of the old FSRP recalibrated to reflect the prevalences, risks, and HRs observed in the sample being studied; and the new FSRP in the FHS, REGARDS, and 3C studies, as well as the calibration χ 2 statistics comparing observed and predicted stroke cases. Values >20 indicate significant lack of calibration (P<0.01). In the calibration analyses using the old FSRP, χ 2 values were >20, and the FSRP significantly overestimated the expected stroke rates in both men and women in FHS and REGARDS and in men in 3C. On the other hand, the new FSRP did not overestimate or underestimate stroke risk in either the FHS (Figure 1 ) or 3C (Table 5 and Figure 2 ) cohorts but overestimated stroke risk in REGARDS (Table 5 and Figure 3 ), especially among black participants. As expected, the recalibrated FSRP performed well, but data on prevalence, risk, and HRs required to perform a recalibration would not be available in most clinical settings where the FSRP is widely recommended and used; the new FSRP can be used in such clinical settings. Tables II and III in 
DISCUSSION Principal Findings and Significance
In the community-based cohort of FHS participants under prospective surveillance for stroke risk factors and incident stroke since 1948, we propose an updated stroke risk function, a new FSRP. Compared with the previous FSRP, it shows better ability to predict future stroke incidence especially in white people across 3 representative cohorts, 2 in the United States and 1 in France. This new FSRP better reflects the current lower risks of incident stroke in whites among both men and women. These lower risks seem to be driven largely by 4 factors: a lower prevalence of smoking; lower mean SBP levels consequent to greater use of antihypertensive medications; a lower impact of 2 traditional stroke risk factors, AF and prevalent nonstroke CVD (because individuals with baseline stroke were excluded in the creation of this risk score); and last, the aging of the at-risk population combined with a diminished impact of DM on stroke risk among individuals >65 years of age compared with younger adults.
Although we advocate the adoption of this new FSRP in lieu of the old FSRP for risk stratification, risk prediction, and estimation of aggregate exposure to vascular risk factors, our finding that the new FSRP, although better than the old, still underperformed in the REGARDS sample emphasizes the need for continued, careful collection of risk factor association data from at-risk populations who are different because of race or an incompletely understood higher or lower stroke risk. In such populations, recalibration of the FSRP with population-specific stroke incidence and risk factor impact can then be undertaken.
Comparison with Prior Studies
Typically, recalibration of a risk profile has been undertaken in comparisons of geographically or ethnically distinct populations. [28] [29] [30] [31] However, because the incidence of stroke has decreased over time, we believed it was appropriate to undertake recalibration of the FSRP in the same Framingham cohort over a new temporal epoch. Our findings on trends in the prevalence and impact of various traditional stroke risk factors are largely concordant with previous publications. 10, 11, 32 Prior data from Framingham and other population samples have documented a decreased mean SBP and an increasing use of antihypertensive medication, and we observed similar trends in the current study sample; however, the impact of a 10-mm Hg rise in SBP was not significantly different across epochs. Framingham data have shown that over the past 50 years, the incidence of smoking, 33 peripheral vascular disease, 34 and coronary artery disease among women has decreased 35 and that the incidence of congestive heart failure has decreased in men (but not in women). 36 However, perhaps because of the increased survival among individuals with these conditions, the overall prevalence of CVD did not vary across epochs in our sample. An increased incidence of DM 37 and prevalence of AF 15, 38 have been previously documented in the FHS and other samples, 39 as has increasing use of antihypertensive medication in all individuals (including diabetics) 40 and increasing use of warfarin in individuals with AF. 41 Our finding of an overall lower stroke incidence in 3C and overall higher stroke incidence in REGARDS has also been previously described, despite this the new FSRP was a more accurate predictor of stroke risk than the old FSRP in each of the validation cohorts. Temporal trends in the HRs associated with several of these stroke risk factors differ from the earlier observations of Whisnant and colleagues 42 that odds ratios associated with individual stroke risk factors did not differ significantly from 1960 to 1984. We believe that this difference is attributable to the longer period of observation in our present study that includes recent decades.
Strengths and Limitations
The strengths of our study are the community-based sample, the reliable and prospective ascertainment of vascular risk factors, the prospective verification of incident stroke with standard clinical definitions, and the excellent continuity among Framingham stroke neurologists, 2 of whom (P.A.W. and C.S.K.) adjudicated most stroke events over the 3 epochs. Limitations of these data include the fact that the FHS and 3C samples are predominantly of European descent, and replication in the more racially and ethnically diverse REGARDS suggests that the FSRP needs to be validated and, if required, recalibrated whenever possible, that is, whenever reliable, local epidemiological data are available. However, the modest discrimination ability of the new FSRP in the REGARDS study should be interpreted with caution considering the short follow-up (5 years) in the REGARDS study. Thus, our findings should be replicated once the majority of RE-GARDS participants have reached 10 years of follow-up, a milestone that will be reached over the next 3 years. Another concern is that at older ages, the competing risk of mortality might affect these risk estimates. However, for the short-term 5-year and 10-year risk predictions we present, starting at ages 55 and 65, it remains appropriate to use models that assume survival to the end of the period.
We chose not to examine the role of newer stroke risk factors (such as plasma homocysteine and serum CRP levels) in our analyses, which are focused on the risk factors originally examined in the FSRP, but our findings suggest that there is room for improvement in discrimination, and adding newer risk factors could help, keeping in mind that any additional parameters selected should be routinely available in a practice or population setting and not too strongly correlated with current risk factors in the FSRP.
Last, the primary purpose of the present analyses was to update the simple clinical FSRP originally described. We expect that this will serve as a more contemporaneous model of the FSRP for use by clinicians. An improved model should also include an exploration of the incremental utility, if any, of novel biomarkers, but such a composite clinical-and biomarker-based risk prediction model may be less widely applicable that this purely clinical one.
Significance and Future Directions
Our observations highlight the need to undertake periodic recalibration of the FSRP. Our data emphasize that assessments of the prognostic accuracy of the FSRP in different populations should use contemporary measures of risk factor impact in the Framingham sample. It is not surprising that an old FSRP based on HRs from an earlier epoch could overestimate contemporary risks in a geographically distant or racially diverse population, 31 just as it does in the current epoch within the Framingham sample itself. Similarly, risk stratification models that assess the incremental prognostic utility of novel biomarkers and clinical risk prediction models should, in our view, be based on periodically recalibrated HRs. Last, the periodic generation of such recalibrated data would serve as a population-based index of the efficacy of our ongoing stroke-related primary prevention efforts and would provide the most updated risk prediction tool for clinicians.
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